Intellectual Property

PATENTS - Patented medicines - Excessive prices

Thursday, September 02, 2021 @ 5:34 AM

Appeal by Alexion Pharmaceuticals from the dismissal of its application for judicial review of a decision of the Patented Medicine Prices Review Board finding that Alexion priced its drug, Soliris, excessively....

To view the full article, Click Here to Subscribe
or sign up for a 14-day FREE Trial

Already a subscriber? Click here to sign in

Featured

Chief Justice of British Columbia Robert Bauman

Ottawa ‘saves’ millions by making tardy judicial appointments; average delay 11 months in 2023

Latest

Business Canada signs Ukraine free-trade deal, sanctions illegal transfer of Ukrainian kids to Russia

Business Federal Court dismisses application to withhold information sought under Access to Information Act

Civil Litigation Court denies developer’s appeal to not pay road improvement costs

Civil Litigation Court dismisses extension to appeal where unit owner owed over $300K in levies

Personal Injury Judge erred in refusing to grant leave to amend statement of claim against Bayer Inc., court rules